MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Mesalamine

Selected References:

  • Allocca M, et al. 2018. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 30(3):316-322.
  • Ban L et al. 2014. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 146 (1):76-84.
  • Banerjee, A et al. 2019. Inflammatory Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. Endocrine, metabolic & immune disorders drug targets, 19(7), 959–974.
  • Chermesh I & Eliakim R. 2004. Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 36:551-2.
  • Diav-Citrin O, et al. 1998. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology; 114:23-28.
  • Gaidos J. & Kane SV. 2020. Medication Adherence During Pregnancy in IBD: Compliance Avoids Complications. Digestive diseases and sciences, 10.1007/s10620-020-06271-w. Advance online publication.
  • Hosseini-Carroll P, et al. 2015. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. World J Gastrointest Pharmacol Ther. 6(4):156-171.
  • Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 168:1393-9.
  • Källén B. 2014. Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring. Scand J Gastroenterol; 49(4):442-8.
  • Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. Obstet Gynecol. 2015;126:401-12.
  • Maliszewska, AM, et al. 2017. Inflammatory bowel disease and pregnancy. Ginekologia Polska, 88(7), 398-403.
  • Marteau P & Devaux CB. 1994. Mesalazine during pregnancy. Lancet 344(8938):1708-1709.
  • Moskovitz DN, et al. 2004. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99(4):656-661.
  • Moretti ME. 1998. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. Theses Canada.
  • Moretti ME, et al. 1998. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. J Clin Pharmacol. 38:867.
  • Nelis GF. 1989. Diarrhoea due to 5-aminosalicylic acid in breastmilk. Lancet 1:383.
  • Nielsen OH, et al. 2014. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 11(2):116-127.
  • Norgård, B et al. 2003. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut, 52(2), 243–247.
  • Pervez, H, et al. 2019. The Impact of Inflammatory Bowel Disease on Pregnancy and the Fetus: A Literature Review. Cureus, 11(9), e5648.
  • Shin T, et al. 2014. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. Syst Biol Reprod Med. 60(6); 373-376.
  • Silverman DA, et al. 2005. Is mesalazine really safe for use in breastfeeding mothers? Gut 54: 170-1.
  • Watanabe, C. et al. 2020. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. Digestive diseases and sciences, 10.1007/s10620-020-06221-6. Advance online publication.
  • Wiersma TK, et al. 2022. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review. Pharmaceutics. 14(6):1241.
  • Xu YL, et al. 2017. Inflammatory bowel disease in pregnancy: A report of 7 cases and review of the literature. Int J Clin Exp Med; 10:5525-32.
  • Yang Q, et al. 2022. Twelve-week peptide-based formula therapy may be effective in inducing remission of active Crohn disease among women who are pregnant or preparing for pregnancy. Nutr Clin Pract. 37(2):366-376.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.